A dose block-randomized, double-blind, placebo-controlled, single dose escalating trial to study pharmacokinetics, pharmacodynamics, and tolerability of Ckd-712 after a single intravenous administration in healthy volunteers

Trial Profile

A dose block-randomized, double-blind, placebo-controlled, single dose escalating trial to study pharmacokinetics, pharmacodynamics, and tolerability of Ckd-712 after a single intravenous administration in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs CKD 712 (Primary)
  • Indications Sepsis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Chong Kun Dang
  • Most Recent Events

    • 03 Feb 2017 Results (n=44) assessing changes in cardiac function after administration of CKD-712 published in the Clinical Drug Investigation.
    • 20 Apr 2016 New trial record
    • 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top